“Coport L 10/5” has been added to your cart. Checkout

Aromet-2

Name: Aromet-2
SKU: SKU-qDg5oBKV
Availability: InStock

Tablet - 500mg+2mg

Aristopharma Limited

Generic: Metformin Hydrochloride + Rosiglitazone

10 Tablets (1 Strip)

Original price was: Tk. 60.Current price is: Tk. 54.

Description

Medicine Overview of Aromet-2 500mg+2mg Tablet

Introduction

Aromet-2 is a combination medicine that helps control blood sugar levels. This medicine is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. It helps in proper utilisation of insulin, thereby lowering the blood sugar level. Aromet-2 should be taken in the dose and duration as advised by your doctor. It must be taken with food to avoid stomach upset. If you miss a dose, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular

Uses of Aromet-2

Type 2 diabetes mellitus

Side effects of Aromet-2

Common

Nausea
Loss of appetite
Taste change
Stomach pain
Diarrhea
Edema (swelling)
Weight gain
Bone fracture
Blurred vision
Respiratory tract infection

How to use Aromet-2

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Aromet-2 is to be taken with food.

How Aromet-2 works

Aromet-2 is a combination of two antidiabetic medicines: Rosiglitazone and Metformin. Rosiglitazone is a thiazolidinedione which works by increasing the body’s sensitivity to insulin. Metformin is a biguanide. It works by lowering sugar production in the liver, delaying sugar absorption from intestines and increasing the body’s sensitivity to insulin.

Quick Tips

Take it as per the dose and duration prescribed by your doctor.

Monitor your blood sugar level regularly while you are taking this medicine.

It can cause hypoglycemia (low blood sugar level) when used with other antidiabetic medicines, alcohol or if you delay or miss a meal.

Always carry some sugary food or fruit juice with you in case you experience hypoglycemic symptoms such as cold sweats, cool pale skin, tremor, and anxiety.

Your doctor may check your liver function regularly. Inform your doctor if you develop symptoms such as abdominal pain, loss of appetite, or yellowing of the eyes or skin (jaundice).

Inform your doctor if you notice weight gain, shortness of breath, irregular heartbeat, or any abnormal swelling.

Brief Description

Indication

Type 2 DM

Adult Dose

Oral Type 2 Diabetes The recommended starting dose of Rosiglitazone/Metformin is 2 mg/500 mg once or twice daily. HbA1c >11% or fasting plasma glucose (FPG) >270 mg/dL, a starting dose of 500 mg/2 mg PO BID may be considered May titrate by increments of 500 mg/2 mg at 2-week intervals, not to exceed 2000 mg/8 mg per day For patients inadequately controlled on Metformin monotherapy, the usual starting dose is 4 mg Rosiglitazone (daily dose) plus the dose of Metformin already being taken. For patients inadequately controlled on Rosiglitazone monotherapy, the usual starting dose is 1000 mg Metformin (daily dose)

Child Dose

Safety and efficacy not established

Renal Dose

Renal impairment
Obtain eGFR before starting metformin
eGFR <30 mL/min/1.73 m²: Contraindicated
eGFR 30-45 mL/min/1.73 m²: Not recommended to initiate treatment
Monitor eGFR at least annually or more often for those at risk for renal impairment (eg, elderly)
If eGFR falls below 45mL/min/1.73 m² while taking metformin, risks and benefits of continuing therapy should be evaluated
If eGFR falls below 30 mL/min/1.73 m²: while taking metformin, discontinue the drug

Contraindication

It is contraindicated in patients with renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels .1.5 mg/dl (males), 1.4 mg/dl (females), or abnormal creatinine clearance), acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma & known hypersensitivity to rosiglitazone maleate or metformin HCl.

Mode of Action

Rosiglitazone: Lowers glucose by improving target cell response to insulin without increasing pancreatic cell secretion; activates nuclear peroxisome proliferator-activated receptor gamma, which influences the production of gene products involved in glucose and lipid metabolism.

Metformin: Biguanide; acts by decreasing endogenous hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization; improves glucose tolerance and lowers both basal and postprandial plasma glucose .

Precaution

Rosiglitazone: should not be used in patients with type 1 diabetes. This should be used with caution in patients with edema. Dose-related weight gain was seen with rosiglitazone alone and rosiglitazone together with other hypoglycemic agents.

Metformin: Monitoring of renal function: Patients with serum creatinine levels above the upper limit of normal should not receive this tablet. In patients with advanced age, the dose should be carefully titrated to establish the minimum dose for adequate glycemic effect, because aging is associated with reduced renal function.

Lactation: not known if crosses into breast milk, avoid

Side Effect

>10%
Edema (6% to 25% ),Upper respiratory infections (16-20%),Diarrhea (12.7% to 14%),Hypoglycemia (12% )

1-10%
Anemia (4% to 7%),Fatigue (6%),Headache (6%),Sinusitis (6%),Arthralgia (5%),Back pain (5%),Viral infection (5%)

Frequency Not Defined (serious)
Angioedema (rare ),Congestive heart failure,Death, from cardiovascular causes,Stevens-Johnson syndrome (rare ),Lactic acidosis (rare ),Hepatotoxicity (rare),Anaphylaxis (rare),Diabetic macular edema,Pleural effusion,Pulmonary edema

Interaction

Additive effect w/ sulfonylureas. Thiazide diuretics, corticosteroids, phenothiazines, OC, sympathomimetics, niacin, Ca channel blockers and isoniazid may exacerbate loss of glycaemic control. ACE inhibitors may reduce fasting blood glucose concentrations. May increase serum level w/ cimetidine.

Potentially Fatal: Concurrent use w/ iodinated contrast agents may increase the risk of metformin-induced lactic acidosis.